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Abstract
Background
The accessibility of services within community pharmacies provides an ideal opportunity to
manage minor ailments, yet over £1.1 billion is spent by the National Health Service (NHS)
in the United Kingdom (UK) in managing minor ailments in high cost settings. There is a
need to review the evidence base around clinical effectiveness of pharmacy-based manage-
ment of minor ailments since the absence of such may lead to under-utilisation of pharmacy
services and non-implementation of available pharmacy service models. This study aimed
to systematically review the methodological approaches used to assess clinical outcomes of
pharmacy-based management of minor ailments in the research literature.
Methods
A systematic review was conducted to identify relevant literature using the following data-
bases: Medline, EMBASE, CINAHL, IPA, CRD, CDSR, and Google Scholar from publication
year 2000 onwards. Studies were included if they evaluated clinical outcomes of pharmacy-
based management of any minor ailments, with or without a comparator setting such as
Emergency Departments (EDs) or general practices. Screening and selection of titles,
abstracts and full texts followed by data extraction and quality assessment (QA) was con-
ducted. Paired researchers, from the team, reviewed papers using a protocol based on the
Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-
P). QA was undertaken using the Critical Appraisal Skills Programme (CASP). Reporting
was conducted in accordance with PRISMA checklist and statements.
Results
A total of 19 studies were included. The majority of studies were observational, conducted in
community pharmacies, and did not use a comparator participant group nor a comparator
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setting. Interventions included counselling, medicines supply and provision of advice on the
management of minor ailments. One study used the randomised controlled trial (RCT)
design with majority of the study utilising observational design. A range of clinical outcomes
including symptom severity, pattern, resolution, and quality of life were reported. Methods
used for the assessment of clinical outcomes were, overall, poorly reported. This included a
lack of information on the development and validation of the data collection tools and the tim-
ing of baseline and follow-up data collection. Adverse clinical outcomes data were collected
by only seven studies.
Conclusions
Currently, there are methodological limitations in the studies that have sought to assess clin-
ical outcomes of pharmacy-based management of minor ailments. Such lack of high quality
evidence may contribute to failings to shift care from high cost settings, such as EDs and
general practices. Generation of high quality evidence is likely to influence public choices
when seeking care for minor ailments. There is scope for development of a core outcomes
set specific to minor ailments management and development of a validated methodology for
measuring such outcomes in a research study.
Background
Minor ailments are defined as ‘common or self-limiting or uncomplicated conditions which
can be diagnosed and managed with minimum or no professional support’ [1]. For example,
cough, cold, hay fever, red eye, minor sprains and pains. Despite the widely acknowledged
expertise of community pharmacists, and pharmacy support staff, and their contribution to
the management of minor ailments, internationally, there is an under-utilisation of pharmacy.
For example, a recent analysis of routinely collected data in hospital emergency departments
(ED) and in general practices in the United Kingdom (UK) demonstrated that between 5%
and 13% of consultations respectively were for minor ailments equating to a cost of £1.1 billion
[2]. Up to 20% of all general practitioner (GP) consultations are known to be for minor ail-
ments consultations alone excluding the data where minor ailments forms a part of a consulta-
tion for a more serious condition [3]. The services of pharmacists in ED and general practices
in managing minor ailments, inclusive of the recruitment of pharmacist independent prescrib-
ers, has recently been introduced in the UK [4].
There is overwhelming support for enhanced pharmacy-based management of minor ail-
ments from pharmacists and associated professional and regulatory bodies across Europe [5–
8]. For example, the Royal Pharmaceutical Society (RPS), the pharmacy regulator in the UK,
supports the enhanced management of minor ailments through community pharmacy. It is
proposed that enhanced management of minor ailments from pharmacy can improve patient
choices in their use of health services, reduce the burden on general practice and ED, increase
patient access to local services for minor ailment management and permit professional devel-
opment opportunities for pharmacists. The government policies also envisage that enhanced
pharmacy assisted self-care would contribute to significant patient health benefits in the longer
term [6].
The existing burden of patients presenting with minor ailments to general practice and ED
highlights the need for further research to identify any gaps between policy and practice. Lack
of adequate evidence may negatively impact on the promotion of relevant practice and policy
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implementation [9–11]. Pharmacy-based services such as the Minor Ailment Scheme (MAS),
which allows free access to the management of minor ailments, have been introduced through
all community pharmacy across Scotland. Patients may present with a minor ailment in a
community pharmacy and expect to receive a structured, formulary-based approach to treat-
ment from a trained, pharmacy-based team. Those who fulfil eligibility criteria such as those
60 years or older, pregnant women and those on income support and allowance, are able to
obtain over–the-counter medicines at no cost, thereby increasing access to treatments for
patients where affordability may be a barrier [12]. In England, however, this particular service
has not been offered at a national level, and Primary Care Trusts in England are yet to imple-
ment a publicly funded minor ailments scheme in their regions. Similar models of Govern-
ment funded pharmacy-based management of minor ailments are uncommon in European
countries [13].
The development of a robust evidence base for pharmacy-based management of minor ail-
ments necessitates that the strengths and limitations of the current evidence is reviewed. Types
of clinical outcomes and their methods of assessment relating to pharmacy minor ailments
management have not previously been systematically reviewed. Measuring clinical outcomes
of minor ailment management in research evaluation presents challenges for data collection,
analysis and interpretation. For example, typically short and self-limiting episodes of illness,
diversity in the range of conditions considered to be minor ailments and lack of appropriate
follow-up methods are inherent issues in minor ailments research. Therefore, it is often diffi-
cult in research studies, including comparative evaluations, to synthesise clinical outcomes
across different illnesses, treatments and settings. Currently, there is no gold standard with
regard to the type of clinical outcome data that should be assessed and the methods of assess-
ment that should be deployed as a component of an intervention study.
This study aimed to systematically review the methods and types of clinical outcomes
assessment used in the evaluation of pharmacy-based minor ailment management.
Methods
A protocol was prepared using Preferred Reporting Items for Systematic Review and Meta-
Analysis Protocols (PRISMA-P, CRD42016050847) (S1 Appendix 1) [14]. An electronic search
of MEDLINE, EMBASE, CINAHL, Centre for Review and Dissemination database (CRD),
Cochrane Database of Systematic Reviews (CDSR), and Google Scholar were undertaken
using Medical Subject Headings (MeSH) and natural language key words, Boolean and prox-
imity (e.g. adj2] operators, truncations () and wild cards ($). The draft search strategy was uti-
lised to perform a scoping search and moderated by the research team before a final version
was agreed for each database. The reference lists of included studies were hand searched to
identify any additional references for inclusion. Authors of conference abstracts were con-
tacted to identify any related full text publications. Referencing software was used to manage
included and excluded references and remove duplicate search results. An example search
strategy is provided in S2 Appendix.
Eligibility criteria
No restrictions to participant demography, study design or publication language were applied.
Evaluations of pharmacy-based management of minor ailments, either with or without a com-
parator service, and from all settings were included from the publication year 2000 onwards.
Studies which did not involve an assessment of follow-up clinical outcomes were excluded
from the review. Both grey and peer reviewed literature were considered. Abstract only publi-
cations were excluded.
Clinical outcomes assessment in minor ailments management: A methodological systematic review
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Screening and selection
Screening was conducted by one pair of researchers in three consecutive stages: screening of
titles; screening of abstracts; screening of full text against the inclusion and exclusion criteria
listed in the protocol (S1 Appendix). Disagreements regarding inclusion were resolved via dis-
cussion within the pairs.
Data extraction and quality assessment
A data extraction tool was developed based on the review aims and objectives, refined,
reviewed and approved by the research team. The tool was piloted using two studies which
were subsequently included in the review. The Critical Appraisal Skills Programme (CASP)
quality assessment tools (for randomised controlled trials (RCT) and cohort studies) were
used to assess study quality [15]. Studies were not excluded based on quality since the quality
assessment of existing literature pertained to the study objectives. Data extraction and quality
assessment were allocated to one of the three pairs of researchers from the team for indepen-
dent review. The research team as whole met and discussed after a pilot data extraction exer-
cise using the draft form. The data extraction form was then finalised and the team met on a
regular basis to ensure that data extraction and quality assessment across the pairs were consis-
tent. Any disagreements were resolved through discussion.
Synthesis
A narrative synthesis of the results was conducted. Due to the methodological nature of the
systematic review, a meta-analysis was not considered appropriate.
Outcome measures
The following outcomes were evaluated in the context of evaluation of minor ailment manage-
ment: a) types of clinical outcomes used and b) methods of clinical outcome measurement.
Guidelines considered for the review
Reporting of this review was based on the PRISMA statement and checklist [16] (S3 Appendix).
Results
A total of 4798 unique titles were screened, of which 19 [1, 17–34] fulfilled eligibility criteria
for inclusion in the review (Fig 1). All eligible papers were published in English language.
Quality assessment
Among the 18 non-RCT studies assessed for quality using the CASP quality assessment tool,
17 studies presented clear study aims (Tables 1 and 2). The majority of studies did not provide
adequate information on the recruitment strategy (n = 12). These included missing informa-
tion on how the participants were identified and followed up. The majority of the included
studies did not indicate whether the follow-up duration was validated in the context of clinical
area being evaluated (n = 13). Confounding factors were only rarely considered when measur-
ing the follow-up outcomes (n = 2).
The only RCT study (18) included in the study was single blinded at participant level. Infor-
mation on the randomisation process was presented clearly. Comparative data on the baseline
characteristics across the control and intervention groups however was not made available
(Table 2). Complete outcome data were reported alongside intention to treat analysis.
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Study design and setting
One study utilised an RCT design [18] and the remainder (n = 18) used observational designs
(Table 3). All included studies involved community pharmacy setting for which the clinical
outcomes were measured [1, 17–34]. Other settings, such as general practice [1, 18, 32] and
EDs [1], were also included as comparators in measuring effectiveness against pharmacy-
Fig 1. PRISMA flowchart of study selection process. databases searched concurrently.
https://doi.org/10.1371/journal.pone.0205087.g001
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based management of minor ailments (Table 3). One study was carried out with pharmacy ser-
vice users as referred by an out-of-hours telephone helpline for non-life threatening conditions
(National Health Service (NHS) Direct) [25].
Types of minor ailments
Studies either focused on one therapeutic area such as cough [18, 30], cold [23], skin condi-
tions [29], gastrointestinal problems [22, 24, 27, 32] or multiple minor ailment areas [1, 17, 20,
21, 26, 28, 33, 34] (Table 4).
Table 1. Quality assessment of included studies (non-RCTs).
Studies
included
Did the
study
address a
clearly
focused
issue?
Was the
cohort
recruited in an
acceptable
way?
Was the
exposure
accurately
measured to
minimise bias?
Was the
outcome
accurately
measured to
minimise bias?
Have the authors
identified all
important
confounding
factors?
Have the authors
taken account of the
confounding factors
in the design and/or
analysis?
Was the
follow-up of
subjects
complete
enough?
Was the
follow-up of
subjects
long
enough?
Are the
results
precise?
Bello (2013)
(17)
Yes Can’t tell Can’t tell Can’t tell Can’t tell No Yes Yes Can’t tell
Bosse (2012)
(19)
Yes Yes Can’t tell Can’t tell Yes No Yes Can’t tell Can’t tell
Coelho
(2014) (20)
No No Can’t tell No No No Yes Can’t tell Can’t tell
Danno (2014)
(21)
Yes Can’t tell Can’t tell No Yes Can’t tell Can’t tell Can’t tell Can’t tell
Hacker
(2012) (22)
Yes Yes Can’t tell Yes Can’t tell Yes Can’t tell Can’t tell Can’t tell
Klimek
(2016) (23)
Yes Can’t tell No No No No Can’t tell Can’t tell Can’t tell
Krishnan
(2000) (24)
Yes Can’t tell Can’t tell Can’t tell No Can’t tell Yes Can’t tell Can’t tell
Lambert
(2013) (25)
Yes Yes Yes Yes Yes No Yes Can’t tell Can’t tell
Mansell
(2015) (26)
Yes Can’t tell Can’t tell No No No Can’t tell Yes Can’t tell
Mehuys
(2009) (27)
Yes Yes Yes Yes Yes No Yes Can’t tell Can’t tell
PANS (2013)
(28)
Can’t tell Can’t tell Can’t tell No No No Can’t tell Can’t tell Can’t tell
Plunkett
(2001) (29)
Yes Can’t tell No Can’t tell No No No Can’t tell Can’t tell
Schulz (2006)
(30)
Yes Can’t tell Can’t tell Can’t tell No No Can’t tell Can’t tell Can’t tell
Sinclair
(2001) (31)
Yes Can’t tell Can’t tell Can’t tell No No Can’t tell Yes Can’t tell
Taylor (2017)
(34)
Yes Can’t tell Can’t tell Can’t tell No Can’t tell Can’t tell Can’t tell Can’t tell
Watson
(2015) (1)
Yes Yes Yes Yes Yes Yes Yes Yes Can’t tell
Westerlund
(2003) (32)
Yes Yes Can’t tell Can’t tell Yes No Yes Can’t tell Can’t tell
Whittington
(2001) (33)
Yes Can’t tell Can’t tell Can’t tell Yes Can’t tell Can’t tell Can’t tell Can’t tell
https://doi.org/10.1371/journal.pone.0205087.t001
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Participants, sample size and recruitment
Sample size calculations or sampling strategies were rarely justified [1, 18, 20] (Table 4). Inclu-
sions were typically stipulated with regard to patient age (e.g. over 17/18 years) and presenting
with the minor ailment subject to study or receiving treatment for a specific minor ailment.
Intervention
The majority of studies stated that pharmacists or members of pharmacy staff delivered the
intervention [17, 18, 20, 21, 24, 26, 29, 32–34]; although there was no clear distinction of their
remit. One study used NHS Direct telephone staff to refer potential participants to out-of-
hours pharmacy settings including referral to other settings such as the general practice [25].
Interventions were also delivered by general practitioners (GP) or nurses in a general practice
[1, 18], and doctors or nurses in ED [1] with the general practice or ED used as a comparator
setting against community pharmacy in the two studies [1, 25].
Nine studies reported that specific training had been provided to staff as either a compo-
nent of the intervention or the research [19, 20, 24, 26–29, 31, 32]. For the majority of studies
(n = 13), it was not specified who paid for the service at the point of care [1, 17–21, 24–28, 32,
34]. The remaining studies reported that minor ailment treatment was either paid for by
patients [22, 23, 29–31, 33] or free at the point of care [33].
Types of clinical outcomes used
Symptoms status. Clinical outcomes were evaluated in relation to symptom severity, pat-
tern (i.e. frequency of specific symptoms) and resolution of symptoms (Table 5). Four studies
evaluated disease-specific symptoms (Table 5). These included evaluation of associated symp-
toms of cough [18], influenza-like illness or ear, nose and throat disorders [21], cold [23] and
gastrointestinal issues [27]. In contrast to the aforementioned, one study utilised a generic tool
to gather data on the symptom status across four minor ailments at baseline and follow-up [1].
Various methods were used to gather clinical data on symptom severity. These included a
Visual Analogue Scale (VAS) [27] and Likert scales ranging from four [21, 22] to 11 points
[23]. One study reported using body mass index (BMI) measures, as a means of detecting
symptoms which were associated with more serious conditions, in addition to measuring
minor ailment specific symptoms [27].
Re-consultation. Re-consultation was assessed in four studies and was intended as a sur-
rogate follow-up measure of clinical outcome assessment [1, 30, 32,33]. Patients in these stud-
ies were asked whether they had subsequently consulted with a GP/physician for the minor
Table 2. Quality assessment of RCT (18) included in the review.
Quality assessment criteria Result of quality assessment
Birring (2017) (18)
Did the trial address a clearly focused issue? Yes
Was the assignment of patients to treatments randomised? Yes
Were all of the patients who entered the trial properly accounted for at is conclusion? Yes
Were patients, health workers and study personnel ’blind’ to treatment? No
Were the groups similar at the start of the trial? Can’t tell
Aside from the experimental intervention, were the groups treated equally? Yes
Can the results be applied in your context (or to the local population)? Can’t tell
Were all clinically important outcomes considered? Yes
Are the benefits worth the harms and costs? Can’t tell
https://doi.org/10.1371/journal.pone.0205087.t002
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Table 3. Characteristics of included studies.
Study Year of
study
Country Study aim Study design Study setting (n)
Bello (2013)
(17)
2011–
13
Nigeria To assess the impact of rural community pharmacist
interventions on self-medications and disease prevalence
Observational Community Pharmacy (1)
Birring (2017)
(18)
2014/15 UK To investigate the efficacy of CS1002, an OTC cough
medicine for cough associated with upper respiratory
tract infection, in a randomised controlled trial
RCT General Practice (4)
Community Pharmacies (12)
Bosse (2012)
(19)
2009/10 USA To evaluate the impact of community pharmacists on
appropriate and successful use of available self-care
treatment options
Observational Community Pharmacies (2)
Coelho (2014)
(20)
2012 Portugal To determine the prevalence of self-medication and to
evaluate the clinical impact of pharmaceutical
counselling
Observational Community Pharmacies (1)
Danno (2014)
(21)
2010/11 France To describe the socio-demographic and clinical
characteristics of patients who seek direct therapeutic
advice from a pharmacist for influenza-like illness or ear,
nose and throat disorders, the types of medicines
dispensed and patient satisfaction with the advice
received
Observational Community Pharmacies (133)
Hacker (2012)
(22)
2012/13 Germany To investigate: characteristics of gastrointestinal
symptoms and patients’ global health status, drug usage
and symptom relief, and patient satisfaction with the
medication
Observational Community Pharmacies (137)
Klimek (2016)
(23)
2014/15 Germany To explore factors affecting efficacy of treatment of
common cold symptoms with an over-the- counter
ibuprofen/ pseudoephedrine combination product
Observational Community Pharmacies (230)
Krishnan
(2000) (24)
1997/98 Germany To assess the outcomes of self-medication and
pharmacist’s counselling in patients and demonstrate the
value of pharmacist involvement in self-medication
process
Observational Community Pharmacies (36)
Lambert (2013)
(25)
2009 UK To determine financial and quality of life impact of
patients calling the NHS Direct telephone helpline from
the perspective of NHS service providers.
Observational Community Pharmacies (unclear), Walk-in centre
(unclear), 999 calls (unclear), general practice
(unclear), ED (unclear), dentist (unclear), do
nothing/treat at home (unclear)
Mansell (2015)
(26)
2012/13 Canada To determine whether patients prescribed minor ailment
treatment by a pharmacist symptomatically improve
within a set time frame.
Observational Community Pharmacies (90)
Mehuys (2009)
(27)
2007 Belgium To investigate self-reported efficacy and frequency of use
of OTC medication for minor complaints.
Observational Community Pharmacies (63)
PANS (2013)
(28)
2012/13 Canada Unclear Observational Community Pharmacies (27)
Plunkett (2001)
(29)
1997 Australia To evaluate whether consumers were satisfied with
advice about skin conditions received from community
pharmacists and to estimate costs and potential savings
to the consumer and government.
Observational Community Pharmacies (126)
Schulz (2006)
(30)
2003 Germany To evaluate the ’real life’ behaviour of consumers with
non-prescription access to ambroxol hydrochloride
cough syrup with special focus on tolerability and the
pattern of product usage.
Observational Community Pharmacies (266)
Sinclair (2001)
(31)
1999 UK To describe the recruitment rate, follow-up rates and
level of symptoms improvement with pharmacy users of
ibuprofen compared with non-users.
Observational Community Pharmacies (61)
Taylor (2017)
(34)
2015/16 Canada To evaluate clinical outcomes in those receiving
pharmacy-based care for 17 minor ailments.
Observational Community Pharmacies (40)
Watson (2015)
(1)
2009 UK To compare health-related and cost-related outcomes of
consultations for symptoms suggestive of minor ailments
in EDs, GPs and community pharmacies.
Observational Community Pharmacies (10)
General Practices (6)
EDs (2)
(Continued)
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ailment after their index consultation. In addition, one study also evaluated re-consultation
within the same setting for the minor ailment presented during the index consultation [1].
Adverse clinical outcomes. Only seven studies included in this review evaluated adverse
clinical outcomes (Table 5). A lack of standardised terminology and data collection tools was
observed in relation to referrals and reporting adverse clinical outcomes. Terminologies used
to refer to adverse clinical outcomes included: side effects, tolerability, drug-drug interactions,
drug related problems (DRPs), overuse and misuse. For example, tolerability was a follow-up
outcome in two studies evaluating the clinical outcomes of pharmacy management of cough
[30] and cold [23]. Tolerability for the study purpose was not defined in either study. In gen-
eral, there was a lack of information provided on the validation of tools utilised in the phar-
macy setting.
Quality of life and health status. Four studies evaluated quality of life outcomes, two of
which used disease-specific tools [18, 24]. Birring [18] used the Leicester Cough Questionnaire
for acute cough at baseline and follow-up. Krishnan [24] used Gastro-intestinal Quality of Life
Index in the assessment of outcomes of patients recommended treatment for dyspepsia at
baseline and follow-up. Neither study provided information on the validation of the tools or
whether they were fit for use in the pharmacy setting. Two studies used more generic tools, for
example, the Generic EuroQoL was used to evaluate quality of life in two studies [1, 25] at both
baseline and follow-up. These studies did not justify whether the tools used were sensitive or
had been validated for use in the context of minor ailments. Health status was evaluated using
global measures in four studies [1, 22, 25, 26].
Methods of clinical outcomes assessment
Data collection tools and their administration. Scant methodological details were
reported around how baseline and/or follow-up clinical data were collected from study partici-
pants (Table 5). Five studies described that baseline clinical data were recorded by the pharma-
cist or member of pharmacy staff in the pharmacy setting, as a component of the clinical
consultation using structured questionnaires [17, 27–29, 33]. Four studies collected baseline
data via self-administered or researcher-administered questionnaires in pharmacy or compar-
ator settings [1, 17, 23, 33].
A limited number of studies attempted to provide information about the validation of the
methods used to collect either baseline or follow-up clinical data (Table 5). Where information
was available on the development of the data collection tools, these were mostly limited to test-
ing of face and content validity. The utility of generic validated quality of life instruments
within the context of the clinical areas evaluated was not clear [1, 25].
Baseline and follow-up data. Five studies did not collect any baseline data [19, 24, 28, 31,
34] (Table 5). Two studies were explicit in reporting the timing of administration of data col-
lection tools: either prior to [1] or after the index consultations [26]. Various timelines were
Table 3. (Continued)
Study Year of
study
Country Study aim Study design Study setting (n)
Westerlund
(2003) (32)
2002 Sweden To investigate the outcomes of a counselling model
designed to help pharmacists care for customers seeking
non-prescription treatment for dyspepsia in community
pharmacies.
Observational Community Pharmacies (6)
Whittington
(2001) (33)
1999 UK To describe community pharmacy management of
minor conditions after referral from one general
practice.
Observational General practice (1)
Community Pharmacies (8)
https://doi.org/10.1371/journal.pone.0205087.t003
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Table 4. Minor ailments evaluated, participants and sample sizes of the included studies.
Study Minor ailment(s) Describe the intervention delivered Describe who delivered
the intervention at each
setting?
Participants Sample size
Bello (2013)
(17)
General body pain,
headache, fever
low back pain,
osteoarthritis
Drug information and counselling
on appropriate health management
strategies for dyspepsia at baseline
and bi-monthly for eighteen months
Community pharmacist Unclear Baseline: 730
Follow-up:
Unclear
Birring (2017)
(18)
Cough Participants were randomised to
CS1002 (Unicough) or simple
linctus (SL), treatment duration was
7 days or until resolution of cough
GP, pharmacist in a
general practice or
community pharmacy.
Participants self-
administered their
assigned medication
Aged18 years who self-referred
themselves to a GP or pharmacist
with an acute cough of <7 days
duration
Severity of at least 60 mm on a
0–100 mm Visual Analogue Scale
Baseline: 163
Follow-up: 159
Bosse (2012)
(19)
Unclear Counselling and advice on self-care/
OTC medicines
Community pharmacists
or pharmacy students
under supervision of
pharmacist
Aged18 years who came into the
pharmacy seeking self-care advice
Baseline: 72
Follow-up: 63
Coelho (2014)
(20)
Minor ailments related to
digestive, respiratory,
dermal, nervous system,
bone/muscle
fever, asthenia,
avitaminosis, ocular
gynaecologist, vascular
sytems.
Participants’ minor health problem
were assessed and eligible
participants targeted for
pharmaceutical counselling,
pharmacological and non-
pharmacological treatments
Community pharmacist Customers with at least one minor
symptom or directly asking for a
non-prescription medicine for their
personal use
Baseline: 298
Follow-up: 268
Danno (2014)
(21)
Influenza-like illnesses
and ear, nose and throat
disorders
Pharmacist conducted symptoms
and medication history taking
followed by recommendation of
medicines and/or advice
Pharmacist Early symptoms of an influenza-like
illnesses or ear, nose or throat
disorder that had appeared <36 h
prior to the pharmacy visit; state of
health not requiring a medical
consultation; receiving at least one
medication from the pharmacist
(without a medical prescription);
aged12 years
Baseline: 573
Follow-up:
unclear
Hacker (2012)
(22)
Upper gastrointestinal
symptoms
Sales of a specific antacid drug
containing hydrotalcite as active
ingredient.
Pharmacy staff Unclear Baseline:548
Follow-up:
Unclear
Klimek (2016)
(23)
Common cold Sales of ibuprofen and
pseudoephedrine combination
product to pharmacy customers
Unclear Aged18 years purchasing
ibuprofen and pseudoephedrine
combination product
Baseline:1770
Follow-up:
Unclear
Krishnan
(2000) (24)
Dyspepsia Patients in the intervention group
received extensive questioning on
factors associated with dyspepsia,
medication counselling and
instructions on dietary regulation
and posture. Patients in the control
group continued to receive the
standard care provided by their
pharmacist
Pharmacist Patients who requested help for
dyspepsia or asked by name for
medication for dyspepsia
Baseline: 205
Follow-up:
Unclear
Lambert
(2013) (25)
Unclear Participants managed by pharmacist
after a triage through NHS Direct
telephone helpline
Pharmacist NHS Direct telephone callers who
had consented to be contacted about
their experience of the service.
Baseline: 3000
Follow-up:
1001
Mansell
(2015) (26)
Acne, cold sores, diaper
rash, canker sores,
seasonal allergies, oral
thrush
insect bites
Pharmacist prescription of an
eligible agent for minor ailment
Community Pharmacist ‘Adults’ prescribed an agent by a
pharmacist for an applicable
condition.
Baseline:125
Follow-up: 125
(Continued)
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Table 4. (Continued)
Study Minor ailment(s) Describe the intervention delivered Describe who delivered
the intervention at each
setting?
Participants Sample size
Mehuys
(2009) (27)
Upper gastrointestinal
symptoms
The pharmacist made a refer-or-
treat decision, following a
counselling protocol based on the
Rome III criteria. Pharmacist then
advised self-treatment options for
patients using pharmacological or
non-pharmacological advice
Pharmacy students under
supervision of pharmacist
Pharmacy customers seeking self-
medication for upper GI symptoms,
aged 18–80 years, speaking Dutch,
and agreeing to pay a follow- up
visit to the pharmacy after 4 weeks
Baseline: 592
Follow-up: 566
PANS (2013)
(28)
Various with Herpes
simplex and allergic
rhinitis as the most
commonly managed
Pharmacist conducting a detailed
assessment of the patient and
making a prescribing decision;
establishing a plan for follow-up
with the patient and conducting
follow-up as required; and following
up as needed with the patient’s
primary care provider
Not specified Unclear Baseline:1002
Follow-up: 871
Plunkett
(2001) (29)
Inflammatory or infective
skin conditions
Participants underwent
dermatological consultations:
diagnosis followed by product sales
Community pharmacist Unclear Baseline: 181
Follow-up:
Unclear
Schulz (2006)
(30)
Cough Sales of a specific brand of cough
medicines from pharmacies from
those who requested the product or
presented with symptoms
Unclear Adolescent consumers who
requested and bought a specific
brand of ambroxol hydrochloride
cough syrup
Baseline: 2707
Follow-up:
Unclear
Sinclair
(2001) (31)
Ibuprofen use for a range
of minor ailments (not
listed)
Ibuprofen tablet or capsule sales
from community pharmacy
Unclear Aged >17 years, able to give
informed consent, and who
purchased themselves (or had
purchased on their behalf) a tablet
or capsule form of ibuprofen
Baseline:555
Follow-up: 522
Taylor (2017)
(34)
Acne, allergic rhinitis,
athlete’s foot, canker sore,
cold sore, diaper rash,
dysmenorrhea,
eczema, folliculitis
headache, heartburn,
haemorrhoids, impetigo,
jock itch,
sprain, ringworm,
oral thrush
Pharmacy-based care (prescription
of eligible agents) of minor ailments
Pharmacist Adults prescribed an agent by a
pharmacist for an applicable
condition. If the medicine was for a
child, a parent could participate
Baseline: 48
Follow-up:
Unclear
Watson
(2015) (1)
Musculoskeletal pain; eye
discomfort;
gastrointestinal
disturbance; upper
respiratory tract-related
Consultation of patients with the
pharmacist or health care
professional in pharmacies, general
practices and EDs including
diagnosis, counselling, advice and
medicines provision
Pharmacist or healthcare
professionals in general
practice and EDs
Aged18 years; requested
treatment or medicines for one or
more of the four included minor
ailments or presented symptoms
associated with these ailments;
presented during specified times
during the day and had face to face
consultation with the staff
Baseline:377
Follow-up: 277
Westerlund
(2003) (32)
Dyspepsia Counselling of participants based on
a counselling model, followed by
provision of self-medication advice
and referrals to physicians
Community pharmacist Aged18 years who asked for a
advice or over the counter treatment
for dyspepsia
Baseline: 319
Follow-up: 130
Whittington
(2001) (33)
Constipation, cough
diarrhoea, dyspepsia
earache, hay fever
head lice, headache
high temperature, nasal
symptoms, sore throat,
vaginal thrush, URTI
Participant consultation with
community pharmacist involving
prescribing, from specific formulary,
for minor ailment where necessary
Community pharmacist Unclear Baseline: 576
Follow-up:
Unclear
https://doi.org/10.1371/journal.pone.0205087.t004
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Table 5. Types of clinical outcomes and methods used for the measurement of clinical outcomes.
Study Baseline clinical outcomes Baseline data
collection method
(personnel
responsible)
Follow-up clinical outcomes Follow-up data
collection
(personnel
responsible)
At what point follow-up
data was captured?
Bello (2013)
(17)
Prevalent illnesses (dyspepsia) and
clinical data such as body
temperature, height, weight, blood
pressure
Questionnaire (self-
administered or
assisted)
Unclear Unclear Unclear
Birring (2017)
(18)
Cough severity, frequency, sleep
quality disruption in the previous
24 hours
Daily diary (self-
administered)
Change of cough severity from
baseline to day 4, 6 and 8 in cough
severity on a VAS Time to
resolution of cough symptoms VAS.
Daily diary
(participant self-
administered)
Daily entries from days
2–8.
Bosse (2012)
(19)
Not available Not available Resolution of symptoms Telephone survey
(researcher)
1 week after consultations
Coelho (2014)
(20)
Reason for the consultation Face-to-face
interview
(pharmacist)
Symptom improvement Face-to-face or
telephone interview
(pharmacist)
After 1 week.
Danno (2014)
(21)
Intensity of 13 listed symptoms of
influenza like illness and impact of
these symptoms on sleep and daily
activities using a global score;
impact on the ability to carry out
daily activities and sleep was
assessed using a 7-point Likert scale
Questionnaire (self-
administered)
Intensity of symptoms; any
concomitant respiratory
pathologies; adherence to the
recommended treatments; use of
any other treatments; impact of the
illness on sleep and daily activities;
and satisfaction with pharmacy
service
Telephone interview
(researcher)
3–5 days after inclusion
Hacker (2012)
(22)
Symptoms (heartburn, acid
regurgitation, epigastric pressure/
pain, feeling of fullness, and others)
and corresponding symptom
severity on a four point scale from
‘non-existent’ to severe, global
health status
Questionnaire (self-
administered)
Symptoms along with
corresponding symptom severity on
a four point scale, effectiveness and
side effects using treatment
satisfaction questionnaire for
medication
Questionnaire
(participant self-
administered)
Participants recorded
their symptoms at 6
predefined time points (5,
10, 15, 30, 60, and 90 min)
after medicines intake.
Klimek (2016)
(23)
Four most bothersome cold
symptoms rated on a 10 point scale;
time from start of cold to first dose
and to number of tablets at each
dosing on the first, second, third or
fourth day of treatment, if
applicable
Questionnaire (self-
administered)
Time to onset of symptom
resolution; the extent of the 11
symptoms after the first dose of
medication on a 10 point scale;
duration of symptom relief after the
first dose Participant responses to
four disease-relevant statements; the
tolerability of ibuprofen and
pseudoephedrine combination
product
Unclear Unclear
Krishnan
(2000) (24)
Gastrointestinal Quality-of-Life
Index
Questionnaire
(unknown)
Gastrointestinal Quality-of-Life
Index
Questionnaire
(unknown)
One week after initial visit
to pharmacy
Lambert
(2013) (25)
VAS quality of life (EQ-5D), health
status
Telephone survey
(researcher)
VAS quality of
life question as included in the
EuroQol-5D (EQ-5D), health status
Telephone survey
(researcher)
Four to six weeks after
initial call.
Mansell
(2015) (26)
Not available Not available Symptom improvement and side
effects
Questionnaire
(participant self-
administered)
Either 7 days (e.g. cold
sores or insect bites) or 30
days (e.g. seasonal
allergies) after having the
prescription filled
Mehuys
(2009) (27)
BMI, nature of GI symptoms e.g.
heartburn; alarm symptoms e.g.
weight loss, vomiting frequency
and duration of the complaints,
medical consultation, and
medication use over the previous
12 months.
Questionnaire (self-
administered)
Symptom resolution, whether
medicines being taken currently and
adherence to advice.
Questionnaire
(participant self-
administered) and
participant medication
diary
Four weeks after first
pharmacy visit.
(Continued)
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used to evaluate follow-up clinical data. The majority of studies used a single time point for the
evaluation of follow-up data with the exception of three studies where multiple time points
were used [18, 26, 31]. Follow-up timelines were specific to each minor ailment in one study
[26]. To illustrate, timelines were either 7 days for cold sores or insect bites, and 30 days from
the index consultation for seasonal allergies based on the length of the symptoms [26]. Symp-
tom or medication diaries were used by patients in two studies [18, 27].
Missing follow-up data. Statistical or methodological techniques used to extrapolate fol-
low-up missing data were applied by one study [22]. This study used the ‘last observation car-
ried forward’ technique as imputation method for missing data over time.
Patient satisfaction measures. This systematic review only sought to review the methods
used to measure patient satisfaction if they were assessed alongside clinical outcomes. Ten
Table 5. (Continued)
Study Baseline clinical outcomes Baseline data
collection method
(personnel
responsible)
Follow-up clinical outcomes Follow-up data
collection
(personnel
responsible)
At what point follow-up
data was captured?
PANS (2013)
(28)
Not available Not available Symptom resolution Survey (unclear) Unclear
Plunkett
(2001) (29)
Diagnosis, as made by the
pharmacist; OTC products
recommended.
Questionnaire
(pharmacist
administered)
Symptoms resolution and perceived
following of pharmacists’ advice.
Telephone survey
(researcher)
Two to six weeks after
consultation
Schulz (2006)
(30)
Pattern of symptoms including
frequency of cough events in the
last 12 months, mean duration of
an event and current pattern
Questionnaire (self-
administered)
Symptoms resolution, and
tolerability and re-consultation with
a physician.
Questionnaire
(participant self-
administered)
Seven days
Sinclair
(2001) (31)
Not available Not available Self-reported information on
ibuprofen usage, reason why the
drug was purchased,
concurrent medication, symptoms
experienced and
health service utilisation.
Questionnaire
(participant self-
administered)
After one week and 2, 6
and 12 months
Taylor (2017)
(34)
Not available Not available Symptom improvement, side-effects
and efficacy of agent.
Questionnaire
(participant self-
administered)
Either 7 day point (e.g.
cold sores/oral thrush) or
30 day point (e.g. seasonal
allergies)
Watson
(2015) (1)
Quality of life (EQ-5D/EQ-VAS),
perceived seriousness and duration
of symptoms.
Questionnaire (self-
administered)
Symptom resolution, quality of life,
re-consultation for the index
ailment and health service
utilisation since their index
consultation and quality of life (EQ-
5D).
Questionnaire
(participant self-
administered)
Post-consultation and at 2
weeks.
Westerlund
(2003) (32)
Common symptoms Interview (method
unclear)
Dyspepsia symptoms resolution,
drug related problems, re-
consultation with a physician
Interview (method
unclear)
Pharmacy customers: 1–2
weeks after pharmacy
visit;
referred customers: 3/4
weeks after pharmacy visit
Whittington
(2001) (33)
Minor condition(s) dealt with,
whether a prescription was
dispensed with item and quantity,
whether an OTC product was
purchased or whether the patient
was referred back to the practice
Study form
(pharmacist
administered)
Re-consultation with GP following
pharmacist consultation.
Unclear Unclear
tools mentioned where available
https://doi.org/10.1371/journal.pone.0205087.t005
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studies did not measure patient satisfaction [17–20, 24, 25, 27, 30, 31, 33]. Studies which uti-
lised patient satisfaction measures varied in their approach, either using categorical questions
[23, 26, 32], Likert scales [26, 29, 34], the Treatment Satisfaction Questionnaire for Medication
[22] or the Medical Interview Satisfaction Scale [1]. One study did not clarify how patient satis-
faction was measured [28]. Two studies reported using validated tools for measuring patient
satisfaction [1, 22].
Results related to clinical outcomes. Improvement of clinical outcomes was reported
across a number of studies [1, 17–28, 30, 32]. Two studies demonstrated that the clinical effec-
tiveness of pharmacy-based minor ailment management was equivalent to, or improved, when
compared with management by other health care professionals in settings such as general
practice or EDs [1, 25].
Discussion
This study aimed to systematically review the methods and types of clinical outcomes in the
evaluation of pharmacy-based management of minor ailments. The results have demonstrated
a lack of high quality, adequately powered studies used in the evaluation of pharmacy-based
minor ailments management. Amongst the studies included, only one study used an RCT
design and there was a lack of adequately powered longitudinal follow-up studies. Within the
included studies, explicit adherence to best practice guidelines [35–38] relating to study meth-
odology was notably lacking. The Medical Research Council Framework signifies the impor-
tance of developing and validating the methodological tools used in the developing and
evaluation of complex interventions [39].
The included studies evaluated a range of clinical outcomes which included symptom status
(inclusive of symptom severity, pattern, and resolution); re-consultation; adverse clinical out-
comes; and quality of life. However, key methodological information was missing around the
choice of clinical outcomes used, the development and validation of data collection tools used
and the timelines of baseline and follow-up outcome data. Given that some of the minor ail-
ments may be self-limiting in nature, lack of validation of the follow-up timeline may affect
estimates of the impact of the interventions. A number of studies evaluated the clinical out-
come data only at the follow-up stages.
A number of studies did not utilise disease-specific clinical outcome assessments. Given the
diverse clinical areas being evaluated, there is scope for the development of core outcome sets
that could be applied to the evaluation of a range of minor ailments. Such core outcome sets
have been developed through consensus around reporting of clinical outcomes in clinical trials
[40]. Consistent outcome sets would also facilitate the ability to conduct meta-analyses of clini-
cal outcomes and direct comparisons between studies.
A minority of the included studies considered evaluation of adverse clinical outcomes data
at follow-up and these were often poorly defined in study reports. Best practice guidelines sug-
gest that study reports include objective information on the incidence and type of clinically rel-
evant adverse events (including any adverse events requiring discontinuation of therapy) as
opposed to the use of general statements such as “well tolerated”. Information on the severity,
frequency, and timing of adverse events are of additional value [40]. Various types of symptom
severity scales were used in the included studies, for both positive clinical outcomes and the
adverse clinical outcomes. In particular, there was a lack of information provided on the vali-
dation of tools in the context of their use in minor ailments and pharmacy as a study setting.
Study settings and disease conditions can have important influence in the validity and reliabil-
ity of symptoms and quality of life assessment tools [41]. Future research should focus on
developing standard practice to address the variance in their use.
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Strengths and limitations
This is the first methodological systematic review of studies evaluating the type of clinical out-
comes and methods used for their assessment in the evaluation of pharmacy-based manage-
ment of minor ailments. Standard guidelines [14, 15] were used to inform the review process.
Being a methodological systematic review, this study did not seek to review in-depth the
impact of pharmacy management of minor ailments on clinical outcomes. This systematic
review applied wider inclusion criteria when considering the selection of studies. Thereby, the
studies included in the review evaluated a broad range of minor ailments. Hence, in-depth
consideration of methodological aspects of research relevant to individual clinical areas were
not possible.
Impact on practice
The lack of high quality research, in terms of methodological rigour, as identified by this sys-
tematic review, is a barrier to the promotion of pharmacy-based services aimed at minor ail-
ments management. In the UK, despite the country leading the reclassification of prescription
only medicines for over-the-counter supply (including pharmacy only status), the burden of
minor ailments in high cost settings still remains a key issue. This review demonstrates a lack
of high quality evidence in relation to the clinical outcomes of pharmacy-based management
of minor ailments; a factor which may contribute to failings to shift care from high cost set-
tings, such as EDs and general practices. Reclassification decisions are often based on the ‘do
no harm’ principle and on the experiences of their use as a prescription medicine and assump-
tion of reduced costs to the health services. The evidence base for pharmacy-based provision
of services and medicines are often ignored in such decisions.
Recommendations for research
The results of this study suggest that future research on pharmacy-based management of
minor ailments should adhere to the following recommendations:
• Utilisation of high quality RCT or longitudinal observational studies informed by best prac-
tice guidelines.
• Use of validated clinical outcome measures to generate high quality evidence. These include
development and use of disease-specific outcomes assessment tools and core-outcome sets
for a range of minor ailments.
• Use of out-of-hours services, online healthcare services, self-care without professional sup-
port, and over-the-counter management in non-pharmacy setting, in addition to pharma-
cist-led services in general practices and ED comparators to community pharmacy-based
models of minor ailments management. Comparative evaluations will be of value to practi-
tioners, policy makers and researchers in terms of identifying service improvement and cost
effectiveness.
• Research studies should distinguish between interventions delivered by pharmacists and
those delivered by support staff under pharmacist supervision in a pharmacy.
• Inclusion of adverse clinical outcomes since they were rarely considered by the included
studies and are particularly important where clinical areas are novel such as in the context of
the evaluation of newly reclassified medicines aimed for pharmacy supply.
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Conclusions
Currently, there are methodological limitations in the studies that have sought to evaluate clini-
cal outcomes of pharmacy-based management of minor ailments with regard to both type and
method of assessing clinical outcomes. Future evaluations of pharmacy-based management of
minor ailments should consider the use of high quality study designs, informed by best practice
methodological guidelines, and validated methods of measuring clinical outcomes. There is
scope for development of a core outcomes set specific to minor ailments management and
development of a validated methodology for measuring such outcomes in a research study.
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MEDLINE/EMBASE literature search strategy and results 
ID Search term Results 
1.  Pharmacy/or Pharmacy Service, Hopsital/ 107603 
2.  Pharmacy.mp. 158845 
3.  Limit 2 to abstracts 86439 
4.  Pharmacies.mp. 26989 
5.  Limit 4 to abstracts 19321 
6.  Pharmaceutical Services/ or Pharmacists/ or Community 
Pharmacy Services/  
138036 
7.  Pharmacist$.mp.  105496 
8.  Limit 7 to abstracts 63990 
9.  Retail clinic$.mp. 251 
10.  Limit 9 to abstracts 153 
11.  Combine 1 to 10 with OR 206140 
12.  Self Medication/ 14360 
13.  Minor ailment$.mp. 602 
14.  Minor illness$.mp. 1040 
15.  Minor injur$.mp. 3718 
16.  Non-urgent.mp. 1762 
17.  Common illness$.mp. 1752 
18.  Common ailment$.mp.  687 
19.  ((minor or common or self-limiting or non-urgent or 
nonemergency or non-emergency) adj3 (ailment or 
illness or sickness or symptom or injury or condition or 
problem)).mp.  
97333 
20.  Limit 19 to abstracts 95888 
21.  Over-the-counter.mp. 16275 
22.  Limit 21 to abstracts 14735 
23.  Otc.mp.  9930 
24.  Limit 23 to abstracts 8708 
25.  Non-prescription.mp.  13638 
26.  Limit 25 to abstracts 8641 
27.  Combine 12 to 26 with OR 137779 
28.  Combine 11 and 27 5631 
29.  Limit 28 to yr=”2000-Current” 4632 
30.  Remove duplicates from 29 3533 
 
 
Appendix 3:  
PRISMA Checklist1 
Section/topic  # Checklist item  
Reported 
Y/N/NA and 
page number 
in the 
manuscript 
file  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Y, 1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review 
registration number.  
Y, 2-3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Y, 3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study 
design (PICOS).  
Y, 5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information 
including registration number.  
Y, 5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) 
used as criteria for eligibility, giving rationale.  
Y, 6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search 
and date last searched.  
Y, 5,6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Y, Appendix 
2 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-
analysis).  
Y, 6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
Y, 6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  Y, 6 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis.  
Y, 6, 7-10 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  NA 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-
analysis.  
Y, 7 
 
 Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  Y, 7-10 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.  NA 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow 
diagram.  
Y 7, Fig 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.  Y 11,12 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Y 8-10  
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates 
and confidence intervals, ideally with a forest plot.  
NA, 
methodological 
systematic 
review  
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  NA, 
methodological 
systematic 
review 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Y 8-10 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  NA 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
Y 25,26 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting 
bias).  
Y 27 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  Y 28 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  Y Online 
submission 
system 
1Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097.doi:10.1371/journal.pmed1000097 
NA: Not applicable 
 
